

DAFTAR PUSTAKA

- Abbas AK, Lichtman AH, Pillai S. Cellular and molecular immunology. 7th ed. Philadelphia, PA: Elsevier/Saunders; 2012
- Abdallah J, George N, Yamasaki T, Ganocy S, Fass R. Most patients with gastroesophageal reflux disease who failed proton pump inhibitor therapy also have functional esophageal disorders. Clin Gastroenterol Hepatol. 2018
- Abdelazim, M. H., Ibrahim, A. A. A., & El-hakeem, A. M. (2021). Association between Gastroesophageal Reflux Disease and Chronic Sinusitis: Salivary and Nasal Pepsin as a Biomarker. International Journal of Medical Arts, 3(2), 1181-1187.
- Adappa ND, Zhang Z, Palmer JN, et al. The bitter taste receptor T2R38 is an independent risk factor for chronic rhinosinusitis requiring sinus surgery. Int Forum Allergy Rhinol. 2014;4(1):3–7
- Albayati, S., Khalaf, F.D (2022). Gastroesophageal reflux disease questionnaire score and endoscopic findings in patients with gastroesophageal reflux disease. Mustansiriya Med J, 18(2)
- Antunes, C., Aleem, A., Curtis, S.A. (2023). Gastroesophageal reflux disease. StatPearls. <https://www.ncbi.nlm.nih.gov/books/NBK441938/>
- Azis, A., Akil, M. A., Djamin, R., Patellongi, I. J., Punagi, A. Q., & Alwi, R. (2019). The Function of Pepsin and pH Levels in the Nasal Secretions Due to Extraesophageal Reflux in Causing Chronic Rhinosinusitis. Indian Journal of Public Health



Research & Development, 10(11).

Baklola, M., Terra, M., Badr, A., Fahmy, F.M., Elshabrawy, E., Hawas, Y., Hady, DA., El-Gilany, A. (2023). Precalence of gastro-oesophageal reflux disease, and its associated risk factors among medical students: a nation-based cross-sectional study. BMC Gastroenterol.

Bardhan, K. D., Strugala, V., &Dettmar, P. W. (2012). Reflux revisited: advancing the role of pepsin. International journal of otolaryngology, 2012, 646901.
<https://doi.org/10.1155/2012/646901>

Barshak MB, Durand ML. The role of infection and antibiotics in adult chronic rhinosinusitis. Laryngoscope Investig Otolaryngol. 2017;2:36.

Bansal, D., Sharma, S., Agarwal, S., Saha, R., & Gupta, N. (2016). Detection of Helicobacter pylori in nasal polyps. Head and neck pathology, 10(3), 306-313.

Becher, A., Dent, J. (2010). Systematic review: ageing and gastro-oesophageal reflux disease symptoms, oesophageal function and reflux oesophagitis. Aliment pharmacol Ther, 22:442-454

Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368(19):1791–9

Ror S, Kalkan IH. Medical treatment of gastroesophageal reflux disease. Turk J Gastroenterol. 2017;28(Suppl 1): S48–S52



- Brook I. Microbiology of chronic rhinosinusitis. *Eur J Clin Microbiol Infect Dis.* 2016;35(7):1059–68
- Buana, A.W. (2022). Nasal pepsin A: biomarker of laryngopharyngeal reflux in chronic rhinosinusitis. *Int J Health Sci.*
- Calvo-Henríquez C, Ruano-Ravina A, Vaamonde P, Martinez-Capoccioni G, Martín-Martín C. Is Pepsin a Reliable Marker of Laryngopharyngeal Reflux? *Otolaryngol Head Neck Surg.* 2017 Sep; 157 [3]: 385-391. doi: 10.1177/0194599817709430
- Chatila, A. T., Nguyen, M. T. T., Krill, T., Roark, R., Bilal, M., & Reep, G. (2020). Natural history, pathophysiology and evaluation of gastroesophageal reflux disease. *Disease-a-Month*, 66(1), 100848.
- Cho GS, Moon BJ, Lee BJ, et al. High rates of detection of respiratory viruses in the nasal washes and mucosae of patients with chronic rhinosinusitis. *J Clin Microbiol.* 2013;51(3):979–84.
- Chuang TW, Chen SC, Chen KT. Current status of gastroesophageal reflux disease: diagnosis and treatment. *Acta Gastroenterol Belg.* 2017;80(3):396–404
- Dabrowski A, Stabuc B, Lazebnik L. Meta-analysis of the efficacy and safety of pantoprazole in the treatment and symptom relief of patients with gastroesophageal reflux disease - PAN-STAR. *Prz Gastroenterol.* 2018;13(1):6–15
- DeGaudio JM. Direct nasopharyngeal reflux of gastric acid is a contributing factor in refractory chronic rhinosinusitis. *Laryngoscope.* 2005;115:946---57.



Dinis P, Subtil J. Helicobacter pylori and laryngopharyngeal reflux in chronic rhinosinusitis. Otolaryngol Head Neck Surg.2006;134:67- 72.

Divakaran, S., Rajendran, S., Thomas, RM., Jacob, J., Kurien, M. (2019). Laryngopharyngeal reflux: symptoms, signs, and presence of pepsin in saliva- a reliable diagnostic triad. Int Arc Otorhinolaryngol, 25(2)

Dy F, Amirault J, Mitchell PD, Rosen R. Salivar y Pepsin Lacks Sensitivity as a Diagnostic Tool to Evaluate Extraesophageal Reflux Disease. J Pediatr. 2016;177:53-8

Eusebi, L.H., Ratnakumaran, R., Yuan, Y., Solaymani-Dodaran, M., Bazzoli, F., Ford, A.C.(2018) Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut.Mar,67(3),430-440

Fisichella PM, Andolfi C, Orthopoulos G. Evaluation of gastroesophageal reflux disease. World J Surg. 2017;41(7):1672– 1677

Fokkens, W. J., Lund, V. J., Hopkins, C., Hellings, P. W., Kern, R., Reitsma, S., ... & Witterick, I. (2020). European position paper on rhinosinusitis and nasal polyps 2020. Rhinology, 58, 1-+.

Fortunato JE, D'Agostino RB Jr, Lively MO. Pepsin in saliva as a biomarker for oropharyngeal reflux compared with 24-hour esophageal impedance/pH monitoring in pediatric patients. Neurogastroenterol Motil. 2017 Feb; 29[2]. doi:



10.1111/nmo.12936

Fraczek M, Guzinski M, Morawska-Kochman M, Krecicki T.
Investigation of sinonasal anatomy via low-dose multidetector
CT examination in chronic rhinosinusitis patients with higher
risk for perioperative complications. *Eur Arch of OtoRhino-
Laryngol.* 2017;274:787-93

Ghazizadeh, M., Noohi, S., & Barati, B. (2019). Role of helicobacter
pylori in chronic rhinosinusitis. *B-ENT*, 15(2), 135-138.

Golovkine G, Faudry E, Bouillot S, et al. *Pseudomonas aeruginosa*
transmigrates at epithelial cell-cell junctions, exploiting sites of
cell division and senescent cell extrusion. *PLoS Pathog.*
2016;12(1):e1005377.

Gomm W, von Holt K, Thome F, et al. Association of proton pump
inhibitors with risk of dementia: a pharmacoepidemiological
claims data analysis. *JAMA Neurol.* 2016;73(4):410–416.

Gyawali CP, Kahrilas PJ, Savarino E, et al. Modern diagnosis of
GERD: the Lyon Consensus. *Gut.* edn. 2018;67:1351–1362

Haenisch B, von Holt K, Wiese B, et al. Risk of dementia in elderly
patients with the use of proton pump inhibitors. *Eur Arch
Psychiatry Clin Neurosci.* 2015;265(5):419–428.

Hanna, B.C., Wormald, P.J. (2012). *Gastroesophageal reflux and
chronic rhinosinusitis.* Wolters Kluwer Health.

Hatemi I, Esatoglu SN. What is the long term acid inhibitor treatment
in gastroesophageal reflux disease? What are the potential
problems related to long term acid inhibitor treatment in



- gastroesophageal reflux disease? How should these cases be followed. Turk J Gastroenterol. 2017;28(Suppl 1):S57–S60
- Hayat JO, Yazaki E, Moore AT, Hicklin L, Dettmar P, Kang JY, Sifrim D. Objective detection of esophagopharyngeal reflux in patients with hoarseness and endoscopic signs of laryngeal inflammation. J Clin Gastroenterol. 2014;48[4]:318-27. doi: 10.1097/MCG. 0000000000000011.
- He Z, O'Reilly RC, Bolling L, Soundar S, Shah M, Cook S, et al. Detection of gastric pepsin in middle ear fluid of children with otitis media. Otolaryngol Head Neck Surg. 2007 Jul; 137 [1]: 59-64. doi: 10.1016/j.otohns.2007.02.002.
- Heda, R., Toro, F., Tombazzi, C.R. (2023). Physiology, pepsin. StatPearls. <https://www.ncbi.nlm.nih.gov/books/NBK537005/>
- Higuera-de-la-Tijera F. Efficacy of omeprazole/sodium bicarbonate treatment in gastroesophageal reflux disease: a systematic review. Medwave. 2018;18(2):e7179
- Hsieh JW, Keller A, Wong M, Jiang R-S, Vossall LB. SMELL-S and SMELL-R: Olfactory tests not influenced by odor-specific insensitivity or prior olfactory experience. Proc of the Nat Academy of Sciences. 2017;114:11275-84
- Hsu J, Avila PC, Kern RC, et al. Genetics of chronic rhinosinusitis: state of the field and directions forward. J Allergy Clin Immunol. 2013;131(4):5
- J WT, Lai CC, Wang YH, et al. Risk of pneumonia in patients with gastroesophageal reflux disease: a population-based cohort



study. PLoS One. 2017;12(8). e0183808.

Hojo, M., Asaoka, D., Shimada, Y., Nojiri, S., & Nagahara, A. (2022). Strategies for discontinuation of proton pump inhibitors (PPIs) in patients with long-term PPI administration: a randomized controlled trial. BMC gastroenterology, 22(1), 1-6.

Jecker P, Orloff LA, Wohlfeil M, Mann WJ. Gastroesophageal reflux disease (GERD), extraesophageal reflux (EER) and recurrent chronic rhinosinusitis. Eur Arch Otorhinolaryngol. 2006;263:664---7

Johnston N, Dettmar PW, Ondrey FG, Nanchal R, Lee SH, Bock JM. Pepsin: biomarker, mediator, and therapeutic target for reflux and aspiration. Ann N Y Acad Sci. 2018; 1434[1]:282-289. doi: 10.1111/nyas. 13729.

Kahrilas PJ, Kia L. Pepsin: A Silent Biomarker for Reflux Aspiration or an Active Player in Extra-Esophageal Mucosal Injury? Chest. 2015;148(2):300-1.

Katle E-J, Hatlebakk JG, Omdal R, Kvaløy JT, Steinsvåg SK. Nasal and salivary pepsin as a biomarker for gastroesophageal reflux in chronic rhinosinusitis. Rhinology 2019; 2: 25-31. doi: 10.4193/RHINOL/19.003

Katzka, D. A., & Kahrilas, P. J. (2020). Advances in the diagnosis and management of gastroesophageal reflux disease. bmj, 371.

Kim DH, Seo Y, Kim KM, Lee S, Hwang SH. Usefulness of Nasal Endoscopy for Diagnosing Patients With Chronic Rhinosinusitis: A MetaAnalysis. Am J Rhinol Allergy. 2019,



- Kim, S.Y., Park, B., Lim, H., Kim, M., Kong, I.G., Choi, H.G (2018).
Gastroesophageal reflux disease increases the risk of chronic
rhinosinusitis: a nested case-control study using a national
sample cohort. *Int Forum Allergy Rhinol*, 00(0)
- Kirsch CFE, Bykowski J, Aulino JM, et al. ACR Appropriateness
Criteria((R)) Sinusitis Disease. *J Am Coll Radiol*
2017;14:S550-9.
- Koeda, M., Tanabe, T., Kitasako, Y., Momma, E., Hoshikawa, Y.,
Hoshino, S., ... & Iwakiri, K. (2021). Saliva secretion is
reduced in mild reflux esophagitis patients. *Esophagus*, 1-9.
- Kroch, D. A., & Madanick, R. D. (2017). Medical treatment of
gastroesophageal reflux disease. *World Journal of Surgery*,
41(7), 1678-1684.
- Kucuksezer, U. C., Ozdemir, C., Akdis, M., & Akdis, C. A. (2018).
Chronic rhinosinusitis: pathogenesis, therapy options, and
more. *Expert opinion on pharmacotherapy*, 19(16), 1805-
1815.
- Liao B, Hu CY, Liu T, et al. Respiratory viral infection in the chronic
persistent phase of chronic rhinosinusitis. *Laryngoscope*.
2014;124(4):832-7.
- Liu, D., Qian, T., Sun, S., & Jiang, J. J. (2020). Laryngopharyngeal
reflux and inflammatory responses in mucosal barrier
dysfunction of the upper aerodigestive tract. *Journal of
Inflammation Research*, 13



Liu Q, Lu X, Bo M, et al. The microbiology of chronic rhinosinusitis with and without nasal polyps. *Acta Otolaryngol.* 2014;134(12):1251–8.

Loehrl TA, Samuels TL, Poetker DM, Toohill RJ, Blumin JH, Johnston N. The role of extraesophageal reflux in medically and surgically refractory rhinosinusitis. *Laryngoscope.* 2012;122:1425-30

London NR, Tharakan A, Rule AM, et al. Air pollutant-mediated disruption of sinonasal epithelial cell barrier function is reversed by activation of the Nrf2 pathway. *J Allergy Clin Immunol.* 2016;138(6):1738.e4.

Luo HN, Yang QM, Sheng Y, Wang ZH, Zhang Q, Yan J, et al. Role of pepsin and pepsinogen: linking laryngopharyngeal reflux with otitis media with effusion in children. *Laryngoscope.* 2014 Jul;124 [7]: E294-300. doi: 10.1002/lary.24538.

Mahdavinia, M., III, L.C (2013). Chronic rhinosinusitis and age: is the pathogenesis different?. *Expert Rev Anti Ther*, 11(1)L1029-1040

Marieb, E. N., & Keller, S. M. (2019). *Essentials of Human Anatomy & Physiology*, Global Edition. Pearson.

Mei, J., Yang, Y. U., Jianxia, M. A., & Xiaofeng, Y. U. (2016). Evaluation of the effectiveness of esomeprazole treatment strategies in the management of patients with gastroesophageal reflux disease symptoms: a meta-analysis.



Die Pharmazie-An International Journal of Pharmaceutical Sciences, 71(5), 285-291

Menezes, M. A., & Herbella, F. A. (2017). Pathophysiology of gastroesophageal reflux disease. World journal of surgery, 41(7), 1666-1671.

Miwa H, Kondo T, Oshima T, Fukui H, Tomita T, Watari J. Esophageal sensation and esophageal hypersensitivity - overview from bench to bedside. J Neurogastroenterol Motil. 2010;16(4):353- 62.

Mizokami Y, Oda K, Funao N, et al. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut. 2018;67(6):1042–1051

Ness-Jensen E, Hveem K, El-Serag H, Lagergren J. Lifestyle intervention in gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2016;14(2):175–182 e171-173.

Niikura R, Yamada A, Hirata Y, et al. Efficacy of vonoprazan for gastroesophageal reflux symptoms in patients with proton pump inhibitor-resistant non-erosive reflux disease. Intern Med. 2018;57(17):2443–2450.

Oakley GM, Curtin K, Orb Q, et al. Familial risk of chronic rhinosinusitis with and without nasal polyposis: genetics or environment. Int Forum Allergy Rhinol. 2015;5(4):276–82.

ak E, Kubat G, Yorulmaz İ. Immunoserologic pepsin detection in the saliva as a noninvasive rapid diagnostic test for



- laryngopharyngeal reflux. *Balkan Med J.* 2015; 32[1]:46-50.
doi: 10.5152/balkanmedj.2015.15824.
- Orb Q, Curtin K, Oakley GM, et al. Familial risk of pediatric chronic rhinosinusitis. *Laryngoscope.* 2016;126(3):739–45.
- Orlandi RR, Kingdom TT, Hwang PH, et al. International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. *Int Forum Allergy Rhinol.* 2016;6 Suppl 1:S22-S209.
- Ozmen S, Yücel OT, Sinici I, Ozmen OA, Süslü AE, Oğretmenoğlu O, et al. Nasal pepsin assay and pH monitoring in chronic rhinosinusitis. *Laryngoscope.* 2008;118:890-4.
- Pandit, S., Boktor, M., Alexander, J. S., Becker, F., & Morris, J. (2018). Gastroesophageal reflux disease: A clinical overview for primary care physicians. *Pathophysiology*, 25(1), 1-11.
- Pilotto A, Franceschi M, Vitale D, Zani- nelli A, Masotti G, Rengo F. Drug use by the elderly in general practice: effects on upper gastrointestinal symptoms. *Eur J Clin Pharmacol* 2006; 62: 65–73.
- Pothoven KL, Norton JE, Suh LA, et al. Neutrophils are a major source of the epithelial barrier disrupting cytokine oncostatin M in patients with mucosal airways disease. *J Allergy Clin Immunol.* 2017;139:1966.
- Przespolewski, E. R., Westphal, E. S., Rainka, M., Smith, N. M., Bates, V., & Gengo, F. M. (2018). Evaluating the effect of six proton pump inhibitors on the antiplatelet effects of clopidogrel. *Journal of Stroke and Cerebrovascular Diseases*,



27(6), 1582-1589.

Ren, J. J., Zhao, Y., Wang, J., Ren, X., Xu, Y., Tang, W., & He, Z. (2017). PepsinA as a marker of laryngopharyngeal reflux detected in chronic rhinosinusitis patients. *Otolaryngology–Head and Neck Surgery*, 156(5), 893-900.

Rimmer J, Hellings P, Lund VJ, et al. European position paper on diagnostic tools in rhinology. *Rhinology*. 2019;57:1-41

Roman S, Gyawali CP, Savarino E, et al. Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: update of the Porto consensus and recommendations from an international consensus group. *Neurogastroenterol Motil*. 2017;29(10):1–15.

Samuels TL, Johnston N. Pepsin as a marker of extraesophageal reflux. *Ann Otol Rhinol Laryngol*. 2010 Mar; 119 [3]: 203-8. doi: 10.1177/000348941011900310

Schleimer RP. Immunopathogenesis of chronic rhinosinusitis and nasal polyposis. *Annu Rev Pathol*. 2017;12:331–57

Schnoll-Sussman, F., & Katz, P. O. (2021). Medical Management of Gastroesophageal Reflux Disease. *The Esophagus*, 428-443.

Sedaghat, A. R. (2018). Chronic rhinosinusitis. *Infections of the ears, nose, throat, and sinuses*, 155-168.

Shinozaki S, Osawa H, Hayashi Y, et al. Vonoprazan treatment improves gastrointestinal symptoms in patients with gastroesophageal reflux disease. *Kaohsiung J Med Sci*. 2017;33(12):616–622.



Siupsinskiene, N., Katutiene, I., Jonikiene, V., Janciauskas, D., & Vaitkus, S. (2018). Intranasal *Helicobacter pylori* infection in patients with chronic rhinosinusitis with polyposis. *The Journal of Laryngology & Otology*, 132(9), 816-821.

Sowa, L., & Baroody, F. M. (2020). Pediatric Rhinosinusitis and Gastroesophageal Reflux. In *Pediatric Rhinosinusitis* (pp. 139-148). Springer, Cham.

Stanforth, K.J., Wilcox, M.D., Chatterm P.I., Brownlee, I.A., Zakhour, M.I., Banecki, K.M., Pearson, J.P. (2022). Pepsin properties, structure, and its accurate measurement: a narrative review. *Ann Esophagus*, 5(31)

Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. *Gut Liver*. 2017;11(1): 27–37

Strugala V, Woodcock AD, Dettmar PW, Faruqi S, Morice AH. Detection of pepsin in sputum: a rapid and objective measure of airways reflux. *Eur Respir J*. 2016;47(1):339-41.

Surdea-Blaga, T., Negrutiu, D. E., Palage, M., & Dumitrascu, D. L. (2019). Food and gastroesophageal reflux disease. *Current medicinal chemistry*, 26(19), 3497-3511.

Syam, A.F., Hapsari, F.C., Makmun, D. 2016. The prevalence and risk factors of GERD among Indonesian medical doctors. *Makara J Health Res*, 20(2):35-40

æzi, M. F., & Sifrim, D. (2018). Assessing old and new diagnostic tests for gastroesophageal reflux disease. *Gastroenterology*,



154(2), 289-301.

Vasu, P. K., Gopalankutty, N. V., & Somayaji, G. (2020). Does laryngopharyngeal reflux disease impair nasal mucociliary transport? A case control prospective study. *International Journal of Otorhinolaryngology and Head and Neck Surgery*, 6(4), 633.

Viazis N, Keyoglou A, Kanellopoulos AK, et al. Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study. *Am J Gastroenterol*. 2012;107(11):1662–1667

Villafuerte-Gálvez JA, Kelly CP. Proton pump inhibitors and risk of *Clostridium difficile* infection: association or causation. *Curr Opin Gastroenterol*. 2018;34(1):11–18

Waleleng, B.J., Simadibratam N., Syam, A.F (2007). The pathophysiology of gastroesophageal reflux disease, *Indon J Gastroenterol Hepatol*, 8(3)

Wang, J., Lang, Q., He, Q., Lan, H., Xiao., Wang, B., Zou, W., Wu, M., Zhao, B., Dettmar, P.W., Cheng, F., Yang, M. (2019). Salivary pepsin as an intrinsic marker for diagnosis of sub-types of gastroesophageal reflux disease and gastroesophageal reflux disease-related disorders. *J Neurogastroenterol Motil*, 26(1)

Wang J, Zhao Y, Ren J, Xu Y. Pepsin in saliva as a diagnostic biomarker in laryngopharyngeal reflux: a meta-analysis. *Eur Arch Otorhinolaryngol*. 2018;275(3):671-8.



Wang YF, Yang CQ, Chen YX, Cao AP, Yu XF, et al. Validation in China of a noninvasive salivary pepsin biomarker containing two unique human pepsin monoclonal antibodies to diagnose gastroesophageal reflux disease. *J Dig Dis*. 2019 Jun; 20 [6]: 278- 287. doi: 10.1111/1751-2980. 12783

Wong E, Inthavong K, Singh N. Comment on the European position paper on diagnostic tools in rhinology - computational fluid dynamics. *Rhinology*. 2019, 10.4193/Rhin19.269.

Wong IW, Omari TI, Myers JC, Rees G, Nair SB, Jamieson GG, et al. Nasopharyngeal pH monitoring in chronic sinusitis patients using a novel four channel probe. *Laryngoscope*. 2004;114:1582---5

Wood AJ, Antoszewska H, Fraser J, et al. Is chronic rhinosinusitis caused by persistent respiratory virus infection? *Int Forum Allergy Rhinol*. 2011;1(2):95–100.

Yaseri, H.F. (2017). Gender is a risk factor in patients with gastroesophageal reflux disease. *Med J Islam Repub Iran*.

Yazdani N, Amoli MM, Naraghi M, et al. Association between the functional polymorphism C-159T in the CD14 promoter gene and nasal polyposis: potential role in asthma. *J Investig Allergol Clin Immunol*. 2012;22(6):406–11

Yosunkaya, M.T. (2022). The effect of gastroesophageal reflux disease on the etiology of rhinosinusitis in adults. *KBB For*, 21(2)

ysel ES, Hong SKS, Strugala V, Slaughter JC, Goutte M, Garrett



CG, et al. Rapid salivary pepsin test: Blinded assessment of test performance in gastroesophageal reflux disease. *Laryngoscope*. 2012;122(6):1312-6.

Zachariah, R. A., Goo, T., & Lee, R. H. (2020). Mechanism and pathophysiology of gastroesophageal reflux disease. *Gastrointestinal Endoscopy Clinics*, 30(2), 209-226.

